N/A N=50 Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
Vitiligo
Primary: Incidence of ≥80% Study Area Repigmentation — 0; 9 study areas — p=0.012
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=67 Bioequivalence Study of Tacrolimus in Healthy Volunteers
Healthy Volunteers
Primary: Area Under the Concentration (AUC 72) — 37434.51; 33716.80 pg.h/mL
N/A N=19 Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System
Hearing Loss · Ear Diseases · Hearing Disorders
Primary: Speech Performance in Quiet After Chronic Use (EO Only) — 89.28; 91.94 percentage of correctly recognized words — p=<0.0001
N/A N=8 A Study of a Novel Multi-Wavelength Laser for Tattoo Removal
Tattoo Removal
Primary: Tattoo Clearing as Rated by Investigator — 4 score on a scale
Phase 1 N=72 A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)
Alzheimer's Disease
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
N/A N=50 Proton Therapy for Early Stage Breast Cancer
Early-Stage Breast Cancer
Primary: Ipsilateral Breast Tumor Recurrence-free Survival — 92 percentage of patients
N/A N=15 Investigation of Non-CE Marked Intermittent Catheters for Females
Retention, Urinary
Primary: Residual Urine at 1st Flow-stop During Nurse Catheterization — 28.6; 0.0; 0.0 mL — p=0.001
N/A N=172 Systematic Multi-domain Alzheimer's Risk Reduction Trial
Dementia · Alzheimer Disease
Primary: Cognitive Change — 0.34; 0.19 z-score — p=0.008
Phase 4 N=284 Penicillin Allergy Testing in STD Clinics
Penicillin Allergy
Primary: Number of Respondents Who Responded YES to Any Question Defining High Risk Penicillin Allergy Using Questionnaire Developed by the Study — 36; 36 Participants
Phase 1 N=23 PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
Advanced Breast Carcinoma · Advanced Malignant Solid Neoplasm · Advanced Prostate Carcinoma
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 2; 0; 0; 0 Participants
N/A N=63 Electro-acupuncture for the Prevention of Taxane Induced Myalgias and Neuropathy
Breast Cancer · Neuropathy
Primary: Change in Brief Pain Inventory-Short Form Score — 1.6; 0.6 Score on a scale — p=0.25
N/A N=46 Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers
Diabetic Foot Ulcer
Primary: Number of Participants With 100% Re-epithelialization — 14; 6 Participants
N/A N=452 Chronic Sleep Deprivation Among the Poor: A Lab-in-the-field Approach
Blood Pressure · Depression
Primary: Sleep Per 24 Hours — 5.61; 5.81; 5.99; 6.23 Hours of sleep/24 hours
N/A N=42 Clinical Evaluation of Two Multifocal Contact Lenses
Presbyopia
Primary: Subjective Comfort Ratings on Insertion — 9.19; 9.47 Units on scale
Phase 4 N=40 Assessing Dextenza Insert After SMILE Procedure
Post Procedural Infection
Primary: Mean Change in Pain — 0.15; 0.20; 0.95; 0.90 Score on a scale from 0-10